Intapp to announce fiscal third quarter 2026 financial results on May 5, 2026
Get Alerts INTA Hot Sheet
Join SI Premium – FREE
PALO ALTO, Calif.--(BUSINESS WIRE)-- Intapp, Inc., (NASDAQ: INTA), the leading governed AI platform for professional firms in highly regulated industries, will report fiscal third quarter 2026 financial results after the market close on May 5, 2026. On that day, management will host a webcast at 5 p.m. ET to discuss the company’s business and financial results.
Investors and other interested parties can access the webcast as follows:
What: Intapp fiscal third quarter 2026 financial results earnings webcast
When: Tuesday, May 5, 2026
Time: 5 p.m. ET
Live webcast: Investors | Intapp, Inc.
Replay: An archived webcast of the event will be accessible from the “Events & presentations” section of the company’s investor relations website at Investors | Intapp, Inc. The replay will be available for 90 days following the live presentation.
About Intapp
Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp’s vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world's top firms trust Intapp’s industry-specific enterprise solutions at intapp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260421092859/en/
Investor contact
David Trone
Senior Vice President, Investor Relations
Intapp, Inc.
[email protected]
Media contact
Jen Mara
Senior Director, Brand Strategy and Communications
Intapp, Inc.
[email protected]
Source: Intapp, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
- Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share